Medical Device Market Overview - The medical device market is projected to exceed $600 billion by 2025, driven by an aging population, rising healthcare costs, and rapid technological advancements in AI and biotechnology [1] - Innovations are leading to the development of sophisticated devices that can diagnose and treat a wider range of conditions with greater precision and effectiveness [1] Tactile Systems Technology - Tactile Systems Technology focuses on at-home therapies for chronic disorders, including lymphedema and chronic pulmonary disease, with products like the Flexitouch Plus system and the new Nimbl™ therapy platform [2][3] - The Nimbl™ device is 40% smaller and 68% lighter than previous generations and connects with the Kylee™ digital application for tracking therapy progress [3] - The company reported a total revenue of $73.2 million for Q2 2024, a 7% increase year-over-year, with adjusted EBITDA of $9.1 million, a 49% increase [4] - Tactile Systems is expanding its sales force and marketing efforts to capitalize on the growing lymphedema market [5] - Analyst consensus rates Tactile Systems as a "Strong Buy" with a price target of $23.00, indicating a 62.20% upside [3][4][6] InfuSystem Holdings - InfuSystem is a national healthcare service provider specializing in outpatient care for medical device manufacturers, focusing on infusion pumps and related services [6] - The company recently entered into distribution agreements to expand its product offerings, including an exclusive deal for the Chemo Mouthpiece® and a partnership with Smith+Nephew [7] - InfuSystem reported revenue of $33.7 million for Q2 2024, a 6% increase year-over-year, with net income rising 64.8% to $0.7 million [8] - The company is pursuing strategic partnerships and acquisitions to broaden its market footprint, including a joint venture with Sanara MedTech Inc. [9] - Analyst consensus rates InfuSystem as a "Strong Buy" with a price target of $13.00, representing a 91.74% upside [8][9]

Financial Data and Key Metrics Changes - InfuSystem reported record net revenue of $33.7 million for Q2 2024, representing a 5.3% sequential growth and a 6.2% increase compared to Q2 2023 [4][6] - Adjusted EBITDA margin improved significantly to 18%, with adjusted EBITDA of $6.1 million, an increase of over $300,000 from the prior year [4][8] - Gross profit for Q2 2024 was $16.7 million, a 5% increase year-over-year, with a gross margin percentage of 49.5% [7] Business Line Data and Key Metrics Changes - Oncology segment revenue increased by $1.5 million, or 9%, driven by higher treatment volumes and improved cash collections [6] - Biomedical Services revenue rose by over $0.5 million, nearly 14%, as the GE contract reached full run rate [6] - Equipment rental and disposable medical supplies categories increased by over $800,000, or almost 13%, due to a new large customer [6] - Pain Management and Wound Care businesses each grew by over $300,000, with Wound Care growing at nearly 190% [6] Market Data and Key Metrics Changes - Operating cash flow for Q2 totaled $2.3 million, slightly below the prior year's amount but up nearly $2 million sequentially [9] - Net capital expenditures increased to $6.7 million, focused on new equipment for rental customers and increased volume in Oncology and Pain Management [9] Company Strategy and Development Direction - The company is focused on less capital-intensive revenue sources, such as Biomedical Services, and initiatives to increase pump utilization [10] - InfuSystem is investing in upgrading its information technology and business applications, with a total expected cost of $3 million to $4 million over 18 to 24 months [11] Management's Comments on Operating Environment and Future Outlook - Management reiterated guidance for high single-digit revenue growth and high teens adjusted EBITDA percentage for the year, expecting the second half to reflect growing momentum [21] - The company is optimistic about new opportunities in biomedical services and partnerships, including a significant biomedical device remediation project [14][25] Other Important Information - The company’s net debt increased to $34 million, with available liquidity of $40.3 million at the end of the quarter [10] - The ratio of total debt-to-adjusted EBITDA was 1.5 times, indicating manageable leverage [10] Q&A Session Summary Question: Comments on leasing activity in Negative Pressure Wound Therapy devices - Management clarified that leases from last year will remain in use until their useful life is over, while the new agreement with Smith+Nephew focuses on referral business [23] Question: Additional color on the biomedical business and GE relationship - Management indicated that new opportunities with GE are being explored, and there are several new partnerships outside of GE in the pipeline [25] Question: Expectations regarding the NOPAIN Act - Management expects the NOPAIN Act to drive revenue growth by increasing the number of customers utilizing non-opioid alternatives for pain management [28][29] Question: Share repurchase authorization details - Management confirmed that some shares were repurchased during the quarter, totaling over $200,000 [30][31] Question: Clarification on negative pressure business and device usage - Management explained that various devices can be used in home settings, and they aim to be device agnostic, allowing clinics to choose based on their preferences [34] Question: Trends in purchasing medical equipment - Management noted that the spike in equipment purchases was driven by a large rental customer and does not expect this level to continue [35]

Financial Performance - Net revenues for Q2 2024 reached $33.7 million, a 6.1% increase from $31.7 million in Q2 2023[8] - Gross profit for Q2 2024 was $16.7 million, compared to $15.8 million in Q2 2023, reflecting a gross margin improvement[8] - Operating income for Q2 2024 increased to $1.9 million, up from $1.2 million in Q2 2023[8] - Net income for Q2 2024 was $717,000, compared to $435,000 in Q2 2023, resulting in a net income per share of $0.03[8] - The company reported a comprehensive income of $716,000 for Q2 2024, compared to $607,000 in Q2 2023[8] - Total net revenue for the three months ended June 30, 2024, was $33.698 million, a 6.2% increase from $31.735 million in the same period of 2023[20] - The company reported a net income of $0.717 million for the three months ended June 30, 2024, compared to a net income of $0.435 million for the same period in 2023, reflecting an increase of 64.8%[49] - Basic earnings per share (EPS) for Q2 2024 was $0.03, up from $0.02 in Q2 2023, while diluted EPS also increased to $0.03 from $0.02[49] Assets and Liabilities - Total current assets as of June 30, 2024, were $32.9 million, an increase from $30.6 million as of December 31, 2023[7] - Total assets increased to $108.5 million as of June 30, 2024, compared to $102.9 million at the end of 2023[7] - Long-term debt rose to $34.2 million as of June 30, 2024, up from $29.1 million at the end of 2023[7] - Total liabilities increased to $55.0 million as of June 30, 2024, compared to $50.6 million at the end of 2023[7] - As of June 30, 2024, total stockholders' equity increased to $53,487,000 from $49,956,000 as of June 30, 2023, reflecting a growth of approximately 7.7%[9] - Total liabilities decreased from $59,386,000 as of June 30, 2023, to $59,303,000 as of June 30, 2024, showing a slight reduction[9] Cash Flow and Investments - Cash provided by operating activities for the six months ended June 30, 2024, was $2,686,000, an increase from $2,301,000 in the prior year[12] - Cash and cash equivalents decreased to $146,000 as of June 30, 2024, from $231,000 as of December 31, 2023[7] - The company reported a net cash used in investing activities of $7,114,000 for the six months ended June 30, 2024, compared to $5,390,000 in the prior year[12] - The company purchased medical equipment totaling $8,796,000 during the six months ended June 30, 2024, compared to $6,994,000 in the same period of 2023, representing an increase of approximately 25.8%[12] Revenue Segmentation - Patient services revenue recognized at a point in time accounted for 54.1% of total net revenues in Q2 2024, up from 52.6% in Q2 2023[20] - Device solutions revenue recognized at a point in time was $8.440 million, representing 25.0% of total revenues, compared to 24.7% in the prior year[20] - Total patient services revenue recognized over time was $18.242 million, which is a 9.3% increase from $16.697 million in the same quarter of 2023[20] - Total revenue accounted for under ASC 606 for the six months ended June 30, 2024, was $52.309 million, a 7.5% increase from $48.487 million in the same period of 2023[22] Debt and Financing - The Revolving Facility under the 2021 Credit Agreement has a gross availability of $75 million, with outstanding draws of $34,464,000, leaving an availability of $40,336,000 as of June 30, 2024[34] - The weighted-average Term Benchmark loan rate as of June 30, 2024, was 7.43%, while the actual ABR loan rate was 9.50%[38] - The Company entered into a First Amendment to the 2021 Credit Agreement, extending the maturity date to April 26, 2028, and increasing the maximum incremental revolving loans from $25 million to $35 million[33] - As of June 30, 2024, the Company was in compliance with all debt-related covenants under the 2021 Credit Agreement, as amended[33] Stock and Equity - The company approved a share repurchase program authorizing the repurchase of up to $20.0 million of its common stock through June 30, 2026, with approximately $0.3 million repurchased as of June 30, 2024[50] - The total fair value of shares vested during the six months ended June 30, 2024, was $747,525, compared to $571,105 for the same period in 2023[53] - The company had 562,512 stock options outstanding at June 30, 2024, with a weighted average exercise price of $7.17[56] Tax and Compliance - The effective tax rate for the three months ended June 30, 2024, was 45.2%, significantly higher than the 30.9% effective tax rate for the same period in 2023[46] - The Company recorded a provision for income taxes of $0.6 million on pre-tax income of $1.3 million for the three months ended June 30, 2024, resulting in an effective tax rate of 45.2%[46] - The company is not currently involved in any legal proceedings that could materially affect its financial condition[48]

Financial Data and Key Metrics Changes - First quarter revenue reached $32 million, marking a 5% increase year-over-year, driven by the Device Solutions segment and higher revenue from the GE Healthcare contract [72][108] - Gross profit for the first quarter was $16.5 million, a 10% increase from the prior year, with gross margin percentage at 51.5%, up 2.3% [29][74] - Adjusted EBITDA for the first quarter was $3.9 million, representing a decrease of $400,000 compared to the previous year [30][74] - Selling, general and administrative expenses totaled $17.3 million, an increase of 15% year-over-year, influenced by nonrecurring expenses and inflation [84] Business Line Data and Key Metrics Changes - The Patient Services segment revenue was slightly lower due to tough comparisons in Oncology and Wound Care, with Oncology experiencing higher billing volumes offset by lower per billing net revenue [4] - The Device Solutions unit saw a 16% year-over-year increase, with strong contributions from biomedical services and equipment sales [72] - Wound Care revenue showed a small increase despite strong prior year sales, with higher treatment revenue offsetting lower equipment sales [83] Market Data and Key Metrics Changes - The company has onboarded approximately 220,000 devices, with a focus on maintaining operational efficiencies as most devices are now in the system [7][9] - The company is seeing a steady stream of opportunities from partnerships with larger companies, particularly in the Biomed and Wound Care sectors [12][90] Company Strategy and Development Direction - The company is evolving into a platform services model, leveraging unique assets and skills to partner with other companies, which is expected to drive long-term growth [12][116] - The focus for 2024 is on maximizing profitability from the biomedical business and ramping up Wound Care initiatives, with expectations for significant contributions in the near future [80][88] - The company anticipates high single-digit revenue growth and adjusted EBITDA in the high teens for the year, with potential for double-digit growth in the future [92][96] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue targets for the year, citing diverse growth initiatives across the business [81] - The company is positioned well to fund continued net revenue growth, supported by strong cash flow and liquidity reserves [78] - Management noted that the first quarter typically shows lower profitability due to seasonality and nonrecurring expenses, with expectations for improvement in subsequent quarters [125][126] Other Important Information - The company is investing in upgrading its information technology and business applications, including a full replacement of its main ERP application [31][111] - The company has a strong liquidity position, with $45.2 million available at the end of the quarter and a modest debt-to-EBITDA ratio of 1.3x [6] Q&A Session Summary Question: What were the reasons behind the 1% growth in the Oncology business? - Management indicated that the growth was impacted by a lower gross-to-net model realizable revenue compared to the previous year, which was an anomaly [45][46] Question: What is the long-term growth expectation for the company? - Management suggested that while long-term growth could be in the mid- to high single digits, there are opportunities for faster growth, particularly with new partnerships [16][41] Question: Are there other potential contracts similar to GE? - Management confirmed that while there are no contracts of the same magnitude as GE currently in the pipeline, there are several smaller agreements being pursued [127][128] Question: How does the company plan to manage G&A expenses moving forward? - Management noted that many of the nonrecurring expenses seen in Q1 will not repeat in future quarters, leading to expected improvements in G&A expenses [125][126] Question: What is the outlook for the Wound Care segment? - Management expressed confidence in the growth of the Wound Care segment, with significant contributions expected as initiatives ramp up [88][92]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____ Commission File Number: 001-35020 INFUSYSTEM HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-3341405 (State or Other Jurisdiction of Incorporation or O ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C., 20549 FORM 10-K _____________________________________________________________ x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to ___________________ Commission File Number: 001-35020 ______________________ ...

Table of Contents x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2023 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Commission File Number: 001-35020 INFUSYSTEM HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-33414 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2023 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from _____ to _____ Commission File Number: 001-35020 INFUSYSTEM HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware 20-3341405 (S ...

InfuSystem Holdings, Inc. (NYSE:INFU) Q2 2023 Earnings Conference Call August 3, 2023 9:00 AM ET Company Participants Joe Dorame - Managing Partner Richard DiIorio - Chief Executive Officer Barry Steele - Chief Financial Officer Carrie Lachance - President and Chief Operating Officer Conference Call Participants Aaron Wukmir - Lake Street Capital Markets Alex Nowak - Craig-Hallum Capital Group Jim Sidoti - Sidoti & Company Operator Hello, and welcome to the InfuSystem Holdings, Inc. Second Quarter 2023 Fina ...

for the quarterly period ended March 31, 2023 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (I.R.S. Employer Identification No.) 3851 West Hamlin Road Rochester Hills, Michigan 48309 (Address of Principal Executive Offices) Registrant's Telephone Number, including Area Code: (248) 291-1210 | Securities Registered Pursuant to Section 12(b) of the Act: | | | | --- | - ...